Aug 27, 2020 9:30am EDT PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMORS
Aug 20, 2020 9:30am EDT PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
Jun 01, 2020 9:30am EDT PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG
Mar 30, 2020 4:00pm EDT PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING
Mar 17, 2020 9:30am EDT PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
Mar 05, 2020 9:30am EST PROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD
Feb 13, 2020 9:30am EST PROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
Dec 20, 2019 4:10pm EST PROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK
Dec 04, 2019 9:30am EST PROCESSA PHARMACEUTICALS PROVIDES AN UPDATE ON POSITIVE RESULTS FROM PCS-499 PHASE 2 TRIAL
